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ABSTRACT
Background Diabetes is a risk factor for respiratory
infection, and hyperglycaemia is associated with
increased glucose in airway surface liquid and risk of
Staphylococcus aureus infection.
Objectives To investigate whether elevation of
basolateral/blood glucose concentration promotes airway
Staphylococcus aureus growth and whether pretreatment
with the antidiabetic drug metformin affects this
relationship.
Methods Human airway epithelial cells grown at
air–liquid interface (±18 h pre-treatment, 30 μM–1 mM
metformin) were inoculated with 5×105 colony-forming
units (CFU)/cm2 S aureus 8325-4 or JE2 or
Pseudomonas aeruginosa PA01 on the apical surface
and incubated for 7 h. Wild-type C57BL/6 or db/db
(leptin receptor-deﬁcient) mice, 6–10 weeks old, were
treated with intraperitoneal phosphate-buffered saline or
40 mg/kg metformin for 2 days before intranasal
inoculation with 1×107 CFU S aureus. Mice were culled
24 h after infection and bronchoalveolar lavage ﬂuid
collected.
Results Apical S aureus growth increased with
basolateral glucose concentration in an in vitro airway
epithelia–bacteria co-culture model. S aureus reduced
transepithelial electrical resistance (RT) and increased
paracellular glucose ﬂux. Metformin inhibited the
glucose-induced growth of S aureus, increased RT and
decreased glucose ﬂux. Diabetic (db/db) mice infected
with S aureus exhibited a higher bacterial load in their
airways than control mice after 2 days and metformin
treatment reversed this effect. Metformin did not
decrease blood glucose but reduced paracellular ﬂux
across ex vivo murine tracheas.
Conclusions Hyperglycaemia promotes respiratory
S aureus infection, and metformin modiﬁes glucose ﬂux
across the airway epithelium to limit hyperglycaemia-
induced bacterial growth. Metformin might, therefore, be
of additional beneﬁt in the prevention and treatment of
respiratory infection.
INTRODUCTION
Hyperglycaemia is associated with increased risk of
Staphylococcus aureus infection in the respiratory
tract,1 2 Hyperglycaemia is a risk factor for nasal
colonisation with S aureus3 increased pathogen load
in cystic ﬁbrosis (CF),4 5 increased exacerbation fre-
quency and poor outcomes from exacerbations in
people with chronic obstructive pulmonary disease
(COPD).1 6 In intensive care, intubated patients
with hyperglycaemia had more S aureus in their
bronchial aspirates and this was associated with
increased glucose concentration in the layer of ﬂuid
that lines the airways (airway surface liquid (ASL)).2
Glucose concentration in human ASL is normally
∼0.4 mM, 12.5 times lower than that of blood.7–9
ASL glucose concentrations are raised in people
with respiratory disease, including acute viral rhin-
itis,10 COPD1 and CF.9 ASL glucose concentrations
are also increased in experimental11 and diabetic
hyperglycaemia10 and are further increased in
people with both respiratory disease and diabetes
mellitus.5 9
We developed an in vitro model of airway
glucose homeostasis and showed that under normal
conditions glucose predominantly diffuses from
blood/interstitial ﬂuid across the respiratory epithe-
lium into the ASL via paracellular pathways, and
this is limited by epithelial permeability.8 12–14
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Key messages
What is the key question?
▸ How does hyperglycaemia promote respiratory
infection with Staphylococcus aureus?
What is the bottom line?
▸ We show that elevation of blood glucose in vivo
and basolateral glucose in vitro promotes the
growth of S aureus in the airway and is
associated with increased glucose ﬂux across the
airway epithelium. These data provide the ﬁrst
mechanistic insights into the association
between hyperglycaemia and increased risk of
respiratory S aureus infection in patients with
acute illness or chronic lung disease.
Why read on?
▸ We also show that pretreatment with the
antidiabetic drug metformin limits the growth
of S aureus in the lung. We provide new
evidence that metformin reduces glucose ﬂux
into the lung by reducing transepithelial
permeability, independently of its known blood
glucose-lowering effects. This highlights a new
potential therapeutic beneﬁt of metformin in
the prevention of lung infection, particularly in
patients with respiratory disease and
hyperglycaemia.
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Uptake via apical and basolateral GLUT transporters also
restricts glucose accumulation in ASL,12–15 and rapid metabol-
ism of glucose helps to maintain low intracellular glucose con-
centrations. This provides a driving force for glucose uptake
and limits the transcellular transport of glucose, leading to equi-
librium between ASL and intracellular glucose concentra-
tions.13 14 In this model, increasing the diffusion gradient for
glucose across the epithelium (eg, hyperglycaemia) and increas-
ing paracellular diffusion of glucose via reduced transepithelial
resistance (RT) (eg, inﬂammation) would result in raised ASL
glucose concentration.12 13 As S aureus growth is promoted by
glucose in microbial culture5 we sought to demonstrate experi-
mentally that hyperglycaemia promotes growth of S aureus in
the airway through modiﬁcation of these processes.
Metformin is used in the clinical treatment of type II diabetes to
reduce blood glucose. However, it has also been reported to
decrease permeability,16–19 exhibit anti-inﬂammatory effects16 20
and increase glucose uptake in epithelial tissues.21–23 We therefore
investigated whether metformin could modify these processes and
contribute to a change in epithelial glucose homeostasis and S
aureus growth.
METHODS
Bacterial culture
S aureus strains 8325-4 and JE2 and Pseudomonas aeruginosa
strain PA01 were used for the experiments. A single colony of
each organism/strain was incubated overnight at 37°C in RPMI
medium. The following day fresh medium was added and
culture grown to log phase, OD600 of 0.5 (about 2×10
7 colony-
forming units (CFU)/ml).
Mouse infection model
To assess the effects of glucose on bacterial growth in the
airways we developed an animal model of S aureus lung infec-
tion, based on previous studies.24–26
Wild-type (WT) or db/db (leptin receptor-deﬁcient) C57BL/6,
6–10 weeks old, were obtained from Harlan (Titlarks Acre,
UK). Where stated, mice were treated with 800 μg metformin
(40 mg/kg) intraperitoneally every day from day 2 before infec-
tion. Blood glucose was measured at the same time each day.
Mice were inoculated intranasally with 1×107 CFU of live or
heat-killed S aureus 8325-4 in 100 μl. Infectious doses were
conﬁrmed by plating out serial dilutions. Twenty-four hours
after infection, mice were culled. Bronchoalveolar lavage (BAL)
ﬂuid was recovered by inﬂating the lungs ﬁve times with 1 ml of
phosphate-buffered saline (PBS) via an excision in the trachea.
Dilutions of BAL ﬂuid were plated out onto brain heart infusion
agar plates to count the CFU. BAL cells were counted by trypan
blue exclusion, centrifuged onto glass slides and stained with
haematoxylin and eosin to identify neutrophils. Interleukin 6
(IL-6) was measured in BAL supernatants by ELISA using manu-
facturer’s protocols (R&D Systems).
The features of this model are an acute weight loss associated
with neutrophilic inﬂux into the airways, which is dependent
upon live bacteria and not seen with heat-killed bacteria.
Despite the use of inbred mice and a single bacterial strain,
there is some variance between degrees of neutrophilia and cell
recovery which may be due to other factors such as cage domin-
ance, which can affect the response to infection. Having estab-
lished this model in WT mice, it gave us a platform to study the
effect of hyperglycaemia on airway infection (see online supple-
mentary ﬁgures 1A–D).
Airway epithelial cell culture
H441 epithelial cells were grown on permeable membrane sup-
ports (Transwells, Corning, USA) at the air–liquid interface to
form conﬂuent polarised monolayers, as previously described.12
Monolayers were pretreated with 0, 0.03, 0.3 or 1 mM metfor-
min (added to the basolateral medium) 18 h before apical inocu-
lation with S aureus. Monolayer RT was measured using an
epithelial voltohmmeter (WPI, UK). The glucose concentration
of the surface liquid overlying H441 monolayers was measured
using glucose oxidase analyser (Analox Instruments, UK), as pre-
viously described.12 Primary human bronchial epithelial (HBE)
cells were obtained from endobronchial brushings and cultured
as previously described.27 Cells were transferred onto transwell
permeable supports and grown at the air–liquid interface to
form conﬂuent monolayers.28
In vitro co-culture model
Bacterial cultures were diluted in glucose-free RPMI medium,
and 5×105 CFU (8325-4 and JE2) or 1×108 CFU (PA01) in
50 μl was applied to the apical surface of H441 or HBE mono-
layers. The basolateral side of the airway epithelial–bacterial
co-cultures was bathed in Krebs salt solution (in mM): NaCl,
117; NaHCO3, 25; KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.2;
CaCl2, 2.5 (equilibrated with 5% CO2 to pH 7.3–7.4).
Hyperglycaemia was modelled by applying basolateral glucose
concentrations of 10, 20 and 40 mM. For co-cultures grown in
bilateral glucose, S aureus cultures were supplemented with
10 mM glucose. Co-cultures were placed in a CO2 incubator at
37°C for 7 h, then each was homogenised and CFU calculated
by plating out serial dilutions.
S aureus culture in H441 epithelial ﬂuid secretions
Apical secretions were obtained from cells grown in the pres-
ence of 10, 20, 40 mM basolateral glucose, with or without
1 mM metformin (18 h), in the presence or absence of heat-
killed S aureus to mimic proinﬂammatory stimuli. Glucose-free
Krebs salt solution (100 μl) was applied to the apical surface of
H441 monolayers and removed after 7 h. The glucose concen-
tration of each sample was normalised to 10 mM to allow detec-
tion of any difference in growth due to factors other than
glucose. 5×105 CFU of S aureus were applied to 100 μl of each
ﬂuid secretion sample in a 96-well plate and incubated for 7 h.
S aureus CFU were calculated as above.
Co-culture cytokine analysis
In parallel 7 h co-cultures, the apical ﬂuid was removed for cyto-
kine analysis using an in-house luminex with reagents from
R&D Systems, UK.
Paracellular L-glucose ﬂux and D-glucose uptake
experiments
Paracellular movement of glucose across H441 monolayers was
measured by analysis of radiolabelled [14C]-L-glucose transe-
pithelial ﬂux. Experiments were initiated by adding 1.0 ml
Krebs salt solution containing 1.0 μCi of [14C]-L-glucose plus
10 mM radiolabelled equivalent glucose to the basolateral side
of the transwells and 0.1 ml of glucose-free Krebs solution to
the apical side. Apical and basolateral samples were taken after
1 h and the concentration of radiolabelled glucose was analysed
using a scintillation counter.
Transepithelial movement of [14C]-L-glucose across ex vivo
mouse tracheas was measured in an Ussing chamber, as previ-
ously described.12
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Figure 1 Comparison of Staphylococcus aureus numbers in BAL ﬂuid of infected db/db and wild-type (WT) mice. Leptin receptor deﬁcient (db/db) or
WT C57BL/6 mice were inoculated with 107 CFU of S aureus strain 8325-4 intranasally. (A) Blood glucose concentration on the day of infection. (B)
Weight measured over the time of the experiment. (C) Number of cells; (D) number of neutrophils; (E) IL-6 concentration in BAL ﬂuid on day 1 after
infection. (F) Percentage weight loss measured during the experiment. (G) Bacterial CFU recovered from BAL ﬂuid on day 1 after infection. Individual
mice are shown as data points, the horizontal bars represent mean ± SEM of n=9–13 (pooled experiments). *p<0.05, **p<0.01, ****p<0.0001. (H)
Correlation of blood glucose concentration with CFU recovered from BAL ﬂuid, n=18. BAL, bronchoalveolar lavage; IL, interleukin.
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[14C]-D-Glucose uptake experiments on H441 monolayers
were performed, as previously described.12
Chemicals and reagents
All chemicals and reagents were obtained from Sigma, Poole,
UK unless otherwise stated.
Statistical analysis
Values are reported as mean±SEM. Statistical analysis was per-
formed using analysis of variance and post hoc Bonferroni mul-
tiple comparison or Student t test. p Values<0.05 were
considered signiﬁcant.
Figure 2 Metformin (MF) reduces airway Staphylococcus aureus numbers in hyperglycaemic mice, without lowering blood glucose. Leptin receptor
deﬁcient (db/db) mice were inoculated with 107 CFU of S aureus strain 8325-4 intranasally. Before infection mice were treated with 200 μl 40 mg/ml
metformin or phosphate-buffered saline (PBS) intraperitoneally. (A) Comparison of bacterial CFU recovered from BAL ﬂuid of untreated and
metformin treated wild-type (WT) and db/db mice on day 1 after infection. (B) Blood glucose concentration on the day of infection. (C) Number of
cells; (D) number of neutrophils; (E) interleukin 6 (IL-6) concentration in BAL ﬂuid on day 1 after infection. Individual mice are shown as data points,
the horizontal bars represent mean ± SEM of n=9–14 ± SEM (pooled experiments), **p<0.01, ***p<0.001. BAL, bronchoalveolar lavage.
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RESULTS
Hyperglycaemia increases S aureus growth in the airways
of infected mice
Mice deﬁcient for the leptin receptor (db/db) exhibited signiﬁ-
cantly higher blood glucose concentrations (17.7±1.6 vs 7.4
±0.1 mM; p<0.01; n=10; ﬁgure 1A) and were heavier
(p<0.001; n=10; ﬁgure 1B) than WT mice. Twenty-four hours
after infection with S aureus 8325-4, there were more inﬂamma-
tory cells, neutrophils and cytokines (IL-6) present in the
airways of db/db than WT mice or naïve mice (non-infected
Figure 3 Staphylococcus aureus growth across airway epithelial monolayers is dependent on basolateral glucose levels and is inhibited by
metformin. Airway epithelia–bacteria co-cultures were grown in the presence of varying concentrations of basolateral glucose (10, 20, 40 mM glucose)
or 10 mM bilateral glucose (10/10) without (black bars) or with pretreatment with metformin (1 mM; 18 h pre-treatment; hatched bars). Bacterial CFU
were measured 7 h after infection (percentage compared with growth in the presence of 10 mM basolateral glucose). (A) H441 and S aureus 8325-4
co-culture, n=9–12; (B) primary human bronchial epithelial cells and S aureus 8325-4 co-culture, n=4; (C) H441 and S aureus JE2 co-culture, n=4; (D)
H441 and Pseudomonas aeruginosa co-culture, n=12. *p<0.05, ****p<0.0001, †p<0.05 compared to 10mM glucose pretreated with metformin.
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WT mice) (p<0.05; n=10–13; ﬁgure 1C, D and E). All infected
mice lost weight after infection (ﬁgure 1F). Crucially, db/db
mice had signiﬁcantly more bacteria in their airways after infec-
tion than WT mice (p<0.01; n=9; ﬁgure 1G), and there was a
direct correlation between blood glucose and CFU (r2=0.8,
p<0.0001; n=18; ﬁgure 1H) supporting clinical observations in
humans.
Metformin reduces airway S aureus growth in diabetic mice
without lowering blood glucose
Metformin treatment signiﬁcantly reduced bacterial load in the
airways of db/db mice compared with PBS treatment (p<0.01;
n=9; ﬁgure 2A), to levels similar to those seen in WT mice
(p>0.05). Surprisingly, this reduction in airway S aureus numbers
occurred despite metformin having no signiﬁcant effect on blood
glucose levels over this period of time (p>0.05; n=10; ﬁgure 2B).
Metformin had no effect on S aureus load in WT mice (p>0.05;
n=9; ﬁgure 2A). There was no difference in total cell (n=10,
ﬁgure 2C) or neutrophil (n=9, ﬁgure 2D) recruitment to the
airways or BAL IL-6 (n=14, ﬁgure 2E) concentration after infec-
tion, between metformin-treated and PBS-treated mice.
Hyperglycaemia increases apical S aureus growth in airway
epithelia–bacteria co-cultures
Increasing basolateral glucose from 10 to 20 or 40 mM in H441
airway epithelial co-cultures produced a stepwise increase in
apical S aureus 8325-4 growth (2.7±0.4×107 to 13.0±2.4×107
CFU/ml in 10 and 40 mM, respectively, p<0.01; n=9,
ﬁgure 3A). Similarly, apical S aureus 8325-4 growth was also
increased by increasing basolateral glucose from 10 mM to
20 mM in primary HBE monolayers (1.8±0.2×107 to 2.5
±0.2×107 CFU/ml respectively; p<0.05; n=4, ﬁgure 3B).
Application of 10 mM glucose to apical and basolateral solutions
signiﬁcantly increased apical S aureus growth compared with
10 mM (basolateral only) control (p<0.05; n=12; ﬁgure 3A).
No S aureus colonies were seen under any condition, in basolat-
eral ﬂuid suggesting that the bacteria did not cross the epithelial
barrier over the 7 h time course. Elevation of basolateral glucose
promoted the growth of S aureus JE2 (p<0.05; n=3; ﬁgure 3C).
Furthermore, the growth of P aeruginosa (PA01), was also pro-
moted by increasing basolateral glucose from 10 to 40 mM
(p<0.05; n=6; ﬁgure 3D).
Epithelial cells secrete a number of proteins and sub-
stances on their apical surface.29 Some have antimicrobial
properties; others could promote the growth of bacteria.
Figure 4 Staphylococcus aureus growth in ﬂuid secretions from H441 monolayers. (A) S aureus growth over 7 h in ﬂuid secretions (with glucose
concentration normalised to 10 mM) obtained from the apical surface of H441 epithelial monolayers after exposure to different concentrations of
basolateral glucose (10, 20, 40 mM glucose; black bars) or 40 mM glucose + metformin (MF) pretreatment (1 mM; 18 h pretreatment; hatched
bars), n=4, or (B) in the presence of heat-killed bacteria, and different concentrations of basolateral glucose (10, 20, 40 mM glucose; black bars) or
40 mM glucose + metformin pretreatment (hatched bars) n=4. (C) S aureus growth over 7 h across H441 airway epithelial monolayers, after
pretreatment with different concentrations of metformin (all in the presence of 10 mM basolateral glucose), n=5. (D) S aureus growth in culture
media only (without cells) containing varying concentrations of metformin, n=4. All data are shown as percentage of control *p<0.05, ***p<0.001,
****p<0.0001.
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Therefore, we tested whether basolateral glucose-induced
changes in H441 ﬂuid secretions inﬂuenced apical bacterial
growth. No effect on S aureus growth was seen in ﬂuid
secretions (normalised for glucose concentration) produced
by different hyperglycaemic conditions in the absence
(ﬁgures 4A) or presence of heat-killed bacteria (ﬁgure 4B).
These data are consistent with basolateral glucose, not other
glucose-dependent factors, as a determinant of apical S
aureus growth.
Metformin inhibits hyperglycaemia-induced S aureus growth
in airway epithelia–bacteria co-cultures
Metformin pretreatment signiﬁcantly reduced apical S aureus
growth at all basolateral glucose concentrations (p<0.05; n=9;
Figure 5 Metformin reduces Staphylococcus aureus-induced cytokine secretion. The concentration (pg/ml) of (A) GM-CSF; (B) IFNγ; (C) IL-1α, (D)
IL-6, (E) MIG/CXCL9; (F) TGF-β was measured in the ﬂuid (50 ml) covering the apical surface of H441 monolayers after 7 h in the absence and
presence of apical S aureus,±metformin pretreatment, n=12. ****p<0.0001. GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN,
interferon; IL, interleukin; MIG, monokine induced by gamma interferon; TGF, transforming growth factor.
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ﬁgure 3A). However, metformin had no signiﬁcant effect on
S aureus growth in co-cultures where glucose was at a concen-
tration of 10 mM in both apical and basolateral solutions
(n=12; ﬁgure 3A). Metformin reduced the growth of S aureus
in a dose-dependent manner (ﬁgure 4C). The lowest dose, 30
μM metformin, reduced apical S aureus growth in the presence
of 10 mM basolateral glucose by 29±10% (p<0.05; n=4).
Metformin had no direct effect on S aureus growth in bacter-
ial culture at any concentration tested (n=4; ﬁgure 4D).
Granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon γ (INFγ), interleukins (IL-1α, IL-6), monokine induced
by gamma interferon (MIG/CXCL9) and transforming growth
factor β (TGFβ) concentrations were raised in the ASL of H441
monolayers after the addition of apical S aureus (p<0.0001;
n=12; ﬁgure 5A–F). All except GM-CSF, were signiﬁcantly
reduced by metformin (p<0.0001; n=12). The concentration of
basolateral glucose had no effect on cytokines produced in the
presence or absence of S aureus or in the presence and absence of
metformin (data not shown).
Metformin reduces ASL glucose and transepithelial
glucose ﬂux
ASL glucose
Glucose concentration of the ASL covering the surface of H441
airway epithelial monolayers increased when basolateral glucose
concentration was raised from 10 to 40 mM (p<0.0001; n=4;
ﬁgure 6A). Metformin treatment produced a signiﬁcant decrease
in ASL glucose from 2.3±0.3 to 1.3±0.3 mM in 40 mM baso-
lateral glucose (p<0.05; n=4).
Cellular glucose uptake
D-Glucose uptake by airway epithelial monolayers was not sig-
niﬁcantly affected by the presence of S aureus in either control
or metformin-treated conditions (p>0.05; n=8; ﬁgure 6B).
Transepithelial resistance (RT) and paracellular glucose ﬂux
Metformin induced a dose-dependent increase of RT in H441
monolayers. Addition of 1 mM metformin increased monolayer
RT from 559±25 to 762±14 Ω.cm
2 (p<0.0001; n=15;
ﬁgure 7A), which was prevented by pretreatment with the AMP
activated protein kinase (AMPK) inhibitor compound C
(p<0.05; n=3; ﬁgure 7B). The addition of S aureus to the
apical surface produced a signiﬁcant decrease in RT at all glucose
concentrations tested (p<0.001; n=6; ﬁgure 7C). Metformin
treatment attenuated the fall in RT caused by apical S aureus
(p<0.01; n=6; ﬁgure 7C) in a dose-dependent manner (ﬁgure
7D). The concentration of glucose bathing the cells had no sig-
niﬁcant effect on RT in either the presence or absence of apical
S aureus (p>0.05; n=6).
The decrease in RT evoked by apical S aureus gave rise to an
increase in the rate of basolateral-to-apical paracellular
L-glucose ﬂux, from 7.3±0.5 to 49.3±4.6 nmoles/min/cm2
(10 mM basolateral glucose; p<0.0001; n=8; ﬁgure 8A).
Metformin signiﬁcantly impaired the rise in L-glucose ﬂux
(p<0.0001; n=8; ﬁgure 8A). Similarly, metformin treatment
signiﬁcantly reduced the L-glucose ﬂux across infected ex vivo
mouse tracheas by 40±5% (p<0.05; n=3; ﬁgure 8B).
DISCUSSION
We have shown for the ﬁrst time that the S aureus load was
increased after inoculation into the airways of hyperglycaemic
db/db mice compared with mice with normal blood glucose
concentrations. These ﬁndings were replicated in an in vitro
human airway epithelial–S aureus co-culture model, where ele-
vation of basolateral glucose promoted apical growth of
S aureus in a dose-dependent manner. We used S aureus 8425-4
in our experiments as it is the standard laboratory strain of
S aureus for genetic and virulence studies. It belongs to an
important lineage of virulent S aureus and methicillin-resistant S
aureus (MRSA) isolates.30 Glucose also promoted the apical
growth of JE2, a strain closely related to the common commu-
nity-associated MRSA clone circulating in the USA (USA300),
indicating that the effect is not strain-speciﬁc.31 In addition, ele-
vation of basolateral glucose promoted the growth of unrelated,
but glucose-using, bacteria P aeruginosa (PA01), indicating rele-
vance of this effect to other respiratory pathogens.
Figure 6 Metformin (MF) lowers airway surface liquid (ASL) glucose concentrations in vitro, but has no effect on epithelial glucose uptake. (A)
Glucose concentration of ASL in the presence of 10 and 40 mM basolateral glucose without (open bars) or with metformin pretreatment (hatched
bars), n=4. (B) Bilateral glucose uptake assessed using radiolabelled glucose (14C-D-glucose) applied to both the apical and basolateral surfaces,
n=7. *p<0.05, ****p<0.0001.
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Figure 8 Metformin (MF) reverses the effect of Staphylococcus aureus infection on paracellular glucose ﬂux across airway epithelium. H441
monolayers with and without 1 mM metformin pretreatment, were infected with S aureus. (A) Paracellular glucose ﬂux measured by adding
radiolabelled L-glucose to the basolateral surface and monitoring its appearance at the apical surface, n=8. (B) Transepithelial L-glucose ﬂux across
ex vivo murine tracheas from S aureus-infected mice pretreated with phosphate-buffered saline (PBS) or metformin, n=3. *p<0.05, ****p<0.0001.
Figure 7 Metformin (MF) reverses the reduction of transepithelial resistance caused by Staphylococcus aureus. The effect of metformin (1 mM, 18 h
pretreatment, hatched bars) on H441 airway epithelial monolayer RT (Ω cm
2) in the (A) absence (n=15) and (B) presence of AMPK inhibitor compound
C (n=3; 80 mM pretreatment for 1 h before addition of metformin). (C) Effect of S aureus addition (7 h; black bars) on untreated (open bars) and
metformin pretreated (hatched bars) H441 monolayer RT, n=6. (D) Effect of different concentrations of metformin on H441 monolayer RT after 7 h
co-culture with apical S aureus, n=5. *p<0.05, **p<0.01, ****p<0.0001. AMPK, activated protein kinase; RT, transepithelial electrical resistance.
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In humans, cross-sectional studies showed an association of
hyperglycaemia with respiratory S aureus infection. People with
diabetes mellitus have increased risk of nasal S aureus colonisa-
tion.3 Intubated patients in intensive care with acute hypergly-
caemia have increased S aureus isolated from bronchial
aspirates.1 2 People admitted to hospital with COPD exacerba-
tions who have hyperglycaemia are more likely to have S aureus
on sputum culture than those with normoglycaemia.1 In CF,
S aureus is an important pathogen, with 22% of adults
(≥16 years) having chronic persistent infection.32 In a cohort
study, 8–21-year-old patients with CF and persistent MRSA
infection were more likely to have related diabetes mellitus than
those who were MRSA negative.33 Our experimental ﬁndings
support a direct causative effect of hyperglycaemia underlying
this association. Hyperglycaemia preceded bacterial growth both
in vivo and in vitro. The effects of elevated basolateral glucose
on bacterial growth could be replicated by direct application of
glucose to the apical compartment in vitro. Effects were not
seen when bacteria were cultured in apical secretions from cells
cultured under different glycaemic conditions, after normalisa-
tion for glucose concentrations, indicating that the effects were
not mediated by changes in other factors, such as mucin secre-
tion, metabolic products or protein glycation.34
Addition of S aureus to the luminal surface of the epithelium
in vitro and in vivo induced a reduction in RT and an increase in
basolateral-to-apical glucose ﬂux. This is consistent with our pre-
vious observations where proinﬂammatory conditions decreased
RTand increased glucose ﬂux,
12 and S aureus increased epithelial
permeability in mouse trachea.35 These data therefore support a
model whereby hyperglycaemia and the effect of S aureus on RT
increase transepithelial glucose ﬂux in vitro and in vivo. As S
aureus uses glucose as a nutrient source, we propose that these
changes promote its growth by increasing nutrient availability.5
A key ﬁnding of this study was that, metformin (40 mg/kg
in mice; 30 μM in cell culture) attenuated glucose-induced
S aureus growth both in vivo and in vitro, at clinically-relevant
doses and concentrations (in humans, the usual metformin dose
is about 15–30 mg/kg/day and plasma concentrations are ∼5–
20 μM36 37).
Metformin appears to prevent apical/luminal growth of S
aureus through an effect on epithelial permeability, with restor-
ation of RT and reduced glucose ﬂux in the presence of S
aureus. We propose that this action, at least in part, inhibits S
aureus growth by limiting apical glucose availability. How met-
formin increases RT in the airway epithelium has not been
described. In renal epithelial cells, metformin directly modiﬁed
epithelial tight junctions via activation of AMPK.18 19 Our
observation that compound C (an AMPK inhibitor) prevented
the elevation of RT by metformin in H441 monolayers provides
evidence for a similar pathway in airway epithelium. Metformin
could indirectly modify epithelial permeability by suppressing
the action of proinﬂammatory cytokines.38 However, metformin
increased RT in the absence of proinﬂammatory agents or
S aureus. Furthermore, although metformin prevented
S aureus-induced proinﬂammatory cytokine secretion in vitro,
we were unable to determine a signiﬁcant effect on the inﬂam-
matory response in vivo, even though we detected a decrease in
glucose ﬂux across ex vivo trachea with metformin.
Metformin thus appears to reduce bacterial growth in the
airway by reducing epithelial permeability and limiting glucose
ﬂux into the airway. We were unable to conﬁrm that metformin
reduced luminal glucose concentrations in mouse airway.
Measurement of glucose in mouse ASL is extremely challenging
and BAL mostly samples distal lung ﬂuid, rather than airway
secretions. Glucose homeostasis differs considerably between
the airways and distal lung.39 Hence, BAL ﬂuid may not provide
insights into processes occurring in the proximal airways.
Additionally, epithelial damage during infection or BAL ﬂuid
collection may cause glucose leak into ASL from blood and
interstitial ﬂuid, leading to contamination of samples. Rapid
glucose use by bacterial and inﬂammatory cells may also affect
ASL glucose concentrations.
Metformin had no direct effect on S aureus growth and critic-
ally, the in vivo effect was independent of any observed changes
in blood glucose concentration. Metformin was shown to have
blood glucose-lowering effects in db/db mice,40 but our treat-
ment protocol was much milder (40 mg/kg compared with
300 mg/kg) and shorter (2 days compared with 2 weeks).40
Metformin similarly did not affect basolateral glucose concen-
tration in our in vitro studies (data not shown).
Metformin reduced S aureus numbers in db/db mice but not
in WT mice, providing further evidence that metformin did not
inhibit bacterial growth via alternative effects on—for example,
airway ion transport or mucus secretion in vivo. Additionally,
metformin did not increase airway epithelial glucose uptake, in
contrast to its role in skeletal muscle where it promotes glucose
uptake.41
In conclusion, S aureus growth in the airways is promoted
by hyperglycaemia, and clinically-relevant concentrations of
metformin signiﬁcantly reduced this glucose-dependent
growth. Metformin decreased transepithelial glucose perme-
ability, at least in part, via activation of AMPK. We propose
that this restricts glucose availability to S aureus, limiting bac-
terial growth. As bacterial resistance to antimicrobial
increases, and there are few new agents in development, there
is increasing need for alternative anti-infective strategies. This
new action of metformin, in addition to its blood glucose
lowering effects, may be of therapeutic beneﬁt in the preven-
tion of respiratory infection, particularly with glucose-using
pathogens such as S aureus and in diseases such as COPD and
CF where hyperglycaemia is associated with accelerated pul-
monary decline. We are now undertaking a clinical trial of
metformin for COPD exacerbations (ISRCTN66148745),
focusing on the clinical utility of this drug for respiratory
infection.
Acknowledgements The authors would like to thank Dr Malcolm Brodlie,
Newcastle University, UK for providing human bronchial epithelial cells and Professor
Alain Filloux, Imperial College London, UK, for providing P aeruginosa.
Contributors DLB, EHB and JPG conceived and designed the experiments. JPG
performed the in vitro and ex vivo experiments and analysed the data. JPG and DBL
wrote the paper. JST designed and performed the in vivo experiments, analysed the
data and contributed to writing and editing the manuscript. SN and SG contributed
to the in vitro experiments. JAL and GMK provided bacteria and microbial reagents.
Funding This work was supported by the Wellcome Trust (grant No: 088304/Z/09/
Z) an enterprise grant from St George’s University of London and a Wellcome Trust
ISSF grant to Imperial College London.
Competing interests None.
Patient consent Obtained.
Ethics approval All animal work was approved by a local ethical review board, as
described by the Animals (Scientiﬁc Procedures) Act 1986, and the work was
licensed by the UK Home Ofﬁce. Bronchial brushings, from which human bronchial
epithelial cells were derived, were performed with ethical approval from the local
research ethics committee, REC reference number: 2001/179.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
844 Garnett JP, et al. Thorax 2013;68:835–845. doi:10.1136/thoraxjnl-2012-203178
Respiratory infection
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor
outcomes in patients admitted to hospital with acute exacerbations of chronic
obstructive pulmonary disease. Thorax 2006;61:284–9.
2 Philips BJ, Redman J, Brennan A, et al. Glucose in bronchial aspirates increases the
risk of respiratory MRSA in intubated patients. Thorax 2005;60:761–4.
3 Tamer A, Karabay O, Ekerbicer H. Staphylococcus aureus nasal carriage and
associated factors in type 2 diabetic patients. Jpn J Infect Dis 2006;59:10–14.
4 Merlo CA, Boyle MP, Diener-West M, et al. Incidence and risk factors for multiple
antibiotic-resistant Pseudomonas aeruginosa in cystic ﬁbrosis. Chest
2007;132:562–8.
5 Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on
growth of respiratory pathogens in cystic ﬁbrosis. J Cyst Fibros 2007;60:101–9.
6 Kupeli E, Ulubay G, Ulasli SS, et al. Metabolic syndrome is associated with increased
risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010;38:76–82.
7 Barker PM, Boyd CA, Ramsden CA, et al. Pulmonary glucose transport in the fetal
sheep. J Physiol 1989;409:15–27.
8 Saumon G, Martet G, Loiseau P. Glucose transport and equilibrium across
alveolar-airway barrier of rat. Am J Physiol 1996;270:L183–L90.
9 Baker EH, Clark N, Brennan AL, et al. Hyperglycemia and cystic ﬁbrosis alter
respiratory ﬂuid glucose concentrations estimated by breath condensate analysis.
J Appl Physiol 2007;102:1969–75.
10 Philips BJ, Meguer JX, Redman J, et al. Factors determining the appearance of
glucose in upper and lower respiratory tract secretions. Intensive Care Med
2003;29:2204–10.
11 Wood DM, Brennan AL, Philips BJ, et al. Effect of hyperglycaemia on glucose
concentration of human nasal secretions. Clin Sci 2004;106:527–33.
12 Garnett JP, Nguyen TT, Moffatt JD, et al. Proinﬂammatory mediators disrupt glucose
homeostasis in airway surface liquid. J Immunol 2012;189:373–80.
13 Kalsi KK, Baker EH, Fraser O, et al. Glucose homeostasis across human airway
epithelial cell monolayers: role of diffusion, transport and metabolism. Pﬂugers Arch
2009;457:1061–70.
14 Pezzulo AA, Gutierrez J, Duschner KS, et al. Glucose depletion in the airway surface
liquid is essential for sterility of the airways. PLoS One 2011;6:e16166.
15 Kalsi KK, Baker EH, Medina RA, et al. Apical and basolateral localisation of GLUT2
transporters in human lung epithelial cells. Pﬂugers Arch 2008;456:991–1003.
16 Myerburg MM, King JD Jr., Oyster NM, et al. AMPK agonists ameliorate sodium
and ﬂuid transport and inﬂammation in cystic ﬁbrosis airway epithelial cells. Am J
Respir Cell Mol Biol 2010;42:676–84.
17 Peng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating
tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell
monolayers. J Nutr 2009;139:1619–25.
18 Zhang L, Jouret F, Rinehart J, et al. AMP-activated protein kinase (AMPK) activation
and glycogen synthase kinase-3beta (GSK-3beta) inhibition induce Ca2
+-independent deposition of tight junction components at the plasma membrane.
J Biol Chem 2011;286:16879–90.
19 Zhang L, Li J, Young LH, et al. AMP-activated protein kinase regulates the assembly
of epithelial tight junctions. Proc Natl Acad Sci USA 2006;103:17272–7.
20 Hallows KR, Fitch AC, Richardson CA, et al. Up-regulation of AMP-activated kinase by
dysfunctional cystic ﬁbrosis transmembrane conductance regulator in cystic ﬁbrosis airway
epithelial cells mitigates excessive inﬂammation. J Biol Chem 2006;281:4231–41.
21 Sakar Y, Meddah B, Faouzi MA, et al. Metformin-induced regulation of the
intestinal D-glucose transporters. J Physiol Pharmacol 2010;61:301–7.
22 Walker J, Jijon HB, Diaz H, et al. 5-aminoimidazole-4-carboxamide riboside (AICAR)
enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK.
Biochem J 2005;385:485–91.
23 Wu SB, Wei YH. AMPK-mediated increase of glycolysis as an adaptive response to
oxidative stress in human cells: Implication of the cell survival in mitochondrial
diseases. Biochim Biophys Acta 2012;1822:233–47.
24 Bartlett AH, Foster TJ, Hayashida A, et al. Alpha-toxin facilitates the generation of
CXC chemokine gradients and stimulates neutrophil homing in Staphylococcus
aureus pneumonia. J Infect Dis 2008;198:1529–35.
25 Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are
required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun
2007;75:1040–4.
26 Kapetanovic R, Jouvion G, Fitting C, et al. Contribution of NOD2 to lung
inﬂammation during Staphylococcus aureus-induced pneumonia. Microbes Infect
2010;12:759–67.
27 Forrest IA, Murphy DM, Ward C, et al. Primary airway epithelial cell culture from
lung transplant recipients. Eur Respir J 2005;26:1080–5.
28 Garnett JP, Nguyen TT, Moffatt JD, et al. Proinﬂammatory mediators disrupt glucose
homeostasis in airway surface liquid. J Immunol 2012;189:373–80.
29 Ali M, Lillehoj E, Park Y, et al. Analysis of the proteome of human airway epithelial
secretions. Proteome Sci 2011;9:4.
30 O’Neill AJ. Staphylococcus aureus SH1000 and 8325-4: comparative genome
sequences of key laboratory strains in staphylococcal research. Lett Appl Microbiol
2010;51:358–61.
31 Kennedy AD, Otto M, Braughton KR, et al. Epidemic community-associated
methicillin-resistant Staphylococcus aureus: recent clonal expansion and
diversiﬁcation. Proc Natl Acad Sci USA 2008;105:1327–32.
32 UKCFRegistry. Annual Data Report 2011. 2013:1–53.
33 Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillin-resistant
Staphylococcus aureus and rate of FEV1 decline in cystic ﬁbrosis. Am J Respir Crit
Care Med 2008;178:814–21.
34 Bae CH, Kim JW, Ye SB, et al. AMPK induces MUC5B expression via p38
MAPK in NCI-H292 airway epithelial cells. Biochem Biophys Res Commun
2011;409:669–74.
35 Phillips JR, Tripp TJ, Regelmann WE, et al. Staphylococcal alpha-toxin causes
increased tracheal epithelial permeability. Pediatr Pulmonol 2006;41:1146–52.
36 Sum CF, Webster JM, Johnson AB, et al. The effect of intravenous metformin on
glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med
1992;9:61–5.
37 Radwan MA, Al Taweel ES, Al-Moghairi AM, et al. Monitoring metformin
in cardiac patients exposed to contrast media using ultra-high-performance
liquid chromatography tandem mass-spectrometry. Ther Drug Monit
2011;33:742–9.
38 Coyne CB, Vanhook MK, Gambling TM, et al. Regulation of airway tight junctions
by proinﬂammatory cytokines. Mol Biol Cell 2002;13:3218–34.
39 Garnett JP, Baker EH, Baines DL. Sweet talk—insights into the nature & importance
of glucose transport in lung epithelium. Eur Respir J 2012;40:1269–76.
40 Shore SA, Williams ES, Zhu M. No effect of metformin on the innate airway
hyperresponsiveness and increased responses to ozone observed in obese mice.
J Appl Physiol 2008;105:1127–33.
41 Hundal HS, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action
involves glucose transporter translocation from an intracellular pool to the plasma
membrane in L6 muscle cells. Endocrinology 1992;131:1165–73.
Garnett JP, et al. Thorax 2013;68:835–845. doi:10.1136/thoraxjnl-2012-203178 845
Respiratory infection
